| 1 |
D'Onofrio A, Silva F, Gano L, Raposinho P, Fernandes C, Sikora A, Wyczółkowska M, Mikołajczak R, Garnuszek P, Paulo A. Bioorthogonal Chemistry Approach for the Theranostics of GRPR-Expressing Cancers. Pharmaceutics 2022;14. [PMID: 36559063 DOI: 10.3390/pharmaceutics14122569] [Reference Citation Analysis]
|
| 2 |
Zhang C, Wang H. Accurate treatment of small cell lung cancer: Current progress, new challenges and expectations. Biochim Biophys Acta Rev Cancer 2022;1877:188798. [PMID: 36096336 DOI: 10.1016/j.bbcan.2022.188798] [Reference Citation Analysis]
|
| 3 |
Wu Y, Berisha A, Borniger JC. Neuropeptides in Cancer: Friend and Foe? Adv Biol (Weinh) 2022;6:e2200111. [PMID: 35775608 DOI: 10.1002/adbi.202200111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Zhao T, Tian J, Wang X, Hao Y, Xu M, Zhao Y, Liu X, Chen Y, Jia C. PACTS-Assisted Thermal Proteome Profiling for Use in Identifying Peptide-Interacting Proteins. Anal Chem 2022. [PMID: 35485935 DOI: 10.1021/acs.analchem.2c00581] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 5 |
Moody TW, Jensen RT. Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide (Part 2): biology and clinical importance in central nervous system and inflammatory disorders. Curr Opin Endocrinol Diabetes Obes 2021;28:206-13. [PMID: 33481421 DOI: 10.1097/MED.0000000000000621] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 6 |
Moody TW, Jensen RT. Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide [Part 1]: biology, pharmacology, and new insights into their cellular basis of action/signaling which are providing new therapeutic targets. Curr Opin Endocrinol Diabetes Obes 2021;28:198-205. [PMID: 33449573 DOI: 10.1097/MED.0000000000000617] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 7 |
Palmioli A, Nicolini G, Tripodi F, Orsato A, Ceresa C, Donzelli E, Arici M, Coccetti P, Rocchetti M, La Ferla B, Airoldi C. Targeting GRP receptor: Design, synthesis and preliminary biological characterization of new non-peptide antagonists of bombesin. Bioorg Chem 2021;109:104739. [PMID: 33626451 DOI: 10.1016/j.bioorg.2021.104739] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 8 |
Moody TW, Ramos-Alvarez I, Jensen RT. Bombesin, endothelin, neurotensin and pituitary adenylate cyclase activating polypeptide cause tyrosine phosphorylation of receptor tyrosine kinases. Peptides 2021;137:170480. [PMID: 33385499 DOI: 10.1016/j.peptides.2020.170480] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Hoppenz P, Els‐heindl S, Beck‐sickinger AG. Identification and stabilization of a highly selective gastrin‐releasing peptide receptor agonist. J Pep Sci 2019;25. [DOI: 10.1002/psc.3224] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 10 |
Zhang L, Eiden LE. Progress in regulatory peptide research. Ann N Y Acad Sci 2019;1455:5-11. [PMID: 31646651 DOI: 10.1111/nyas.14260] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Majumder J, Taratula O, Minko T. Nanocarrier-based systems for targeted and site specific therapeutic delivery. Adv Drug Deliv Rev 2019;144:57-77. [PMID: 31400350 DOI: 10.1016/j.addr.2019.07.010] [Cited by in Crossref: 99] [Cited by in F6Publishing: 107] [Article Influence: 24.8] [Reference Citation Analysis]
|
